| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 37
| Issue : 3 | Page : 152-160 |
|
|
Role of bioactive collagen peptide in the management of monoidoacetate induced osteoarthritis and its comparison with diacerein in rat model: An experimental study
Ravi Kant1, Parul Rao2, Gyaneshwer Tank3, Rohit Gupta4
1 Department of Orthopaedics, SN Medical College, Agra, India
2 Department of Pathology, KD Medical College, Uttar Pradesh, India
3 Department of Orthopaedics, LLRM Medical College, Meerut, Uttar Pradesh, India
4 IG ESI Hospital, Delhi, India
Correspondence Address:
Ravi Kant
Department of Orthopaedics, S N Medical College, Agra, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jbjd.jbjd_32_22
|
|
|
Osteoarthritis is the most common joint disorder. Currently, there are no stabilized pharmacological agents capable of retarding the progression or preventing OA. This is a fundamental and important area of current research. Therefore, the present study was to investigate the action of Bioactive Collagen peptide against Monosodium Iodoacetate induced Osteoarthritis in rat models and its comparison with Diacerein. Nine experimental groups were taken. Osteoarthritis was induced by intraarticular injection of Monosodium Iodoacetate (MIA) in knee joints. Bioactive Collagen peptide was given to groups 7, 8 and 9 for 1, 2 and 3 months respectively, then histopathological examination was done. Diacerein was given to groups 4, 5 and 6 for 1, 2 and 3 months respectively followed by histopathological scoring. Significant (P < 0.05) chondroprotection was observed after treatment of Bioactive Collagen peptide when compared with MIA control group as well as Placebo treated group. Significant improvement was also observed when compared with Diacerein treated groups for 1 and 2 monthsIt was concluded that both Bioactive Collagen Peptide and Diacerein are potent chondroprotective agent, but Collagen peptide is far better than Diacerein. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
